📰 Imdc Risk News
Imdc Risk News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Imdc Risk. Real-time updates on events, politics, business and more.
October 30, 2023
Explore statistics behind and possible patient presentations of advanced renal cell carcinoma (RCC), with insight into IMDC risk stratification that may influence treatment strategies and outcomes.
April 26, 2023
The panel closes their discussion with a look at the standards for genetic counseling for patients with non-clear cell RCC.
April 26, 2023
The panel discusses the best approaches to treating patients with non-clear cell RCC.
April 12, 2023
Mehmet Asim Bilen, MD, explains how he would treat a patient with renal cell carcinoma who had disease progression after adjuvant therapy.
April 12, 2023
The panel discusses recent clinical trial data in the adjuvant treatment of metastatic renal cell carcinoma.
March 31, 2023
The panel discusses the use of quality-of-life clinical trial data in metastatic renal cell carcinoma and how liver and brain metastases affect treatment decision-making.
March 31, 2023
Mehmet Asim Bilen, MD, details how he approaches IO/TKI therapy for patients with renal cell carcinoma with bone metastases.
March 23, 2023
Drs Moshe Ornstein and Mehmet Asim Bilen review updated data from the CheckMate 9ER and CLEAR trials investigating combination treatments for metastatic renal cell carcinoma.
March 23, 2023
Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.